Baroness Amos to lead NHS maternity and neonatal investigation
Mr Streeting has been meeting bereaved and harmed families who have been let down by maternity and neonatal services across the country, including in some of the worst affected trusts, DHSC added.
In June, he announced that a national investigation into 'systemic' failures in NHS maternity care had been launched by the Government after families were 'gaslit' in their search for the truth.
Baroness Amos is master of University College, Oxford, and was a UK Government minister and a senior official at the United Nations.
Mr Streeting said: 'I have been appalled by the many harrowing stories I've heard from mothers and fathers let down by the NHS.
'Families asked for fresh eyes, independence and compassion – and that's why I've appointed Baroness Amos. Valerie has an outstanding record of leadership and driving change, nationally and internationally. She will work closely with families to uncover the truth, confront problems and drive the improvements needed so every woman and baby receives safe, high-quality care.
'Through our Plan for Change, we will rebuild the NHS to ensure no family suffers like this again.'
Baroness Amos said: 'I will carry the weight of the loss suffered by families with me throughout this investigation. I hope that we will be able to provide the answers that families are seeking and support the NHS in identifying areas of care requiring urgent reform.'
The investigation will look at up to 10 services in the country. It will also review the maternity and neonatal system, bringing together the findings of past reviews into one national set of actions, the DHSC said.
It will begin work this summer and produce an initial set of national recommendations by December.
The 10 maternity and neonatal units will be decided by Baroness Amos and her team, alongside the terms of reference of the investigation, which are being developed with families who have experiences of maternity and neonatal care, including in Leeds, Sussex and Nottingham, the DHSC added.
The investigation is separate from the National Maternity and Neonatal Taskforce, which will be made up of a panel of experts and families, and chaired by Mr Streeting.
Gill Walton, chief executive of the RCM, said: 'We are pleased to hear of the appointment of Baroness Amos as chair of the rapid review. She has a reputation for taking a thoughtful and strategic approach and we welcome her fresh insight into maternity and neonatal safety.
'It is absolutely vital, though, that this review gets under way quickly. When he announced it in June, we welcomed Wes Streeting's commitment to publishing the review by Christmas, a promise he repeated at the Progress in Partnership summit on maternity and neonatal safety last month.
'However, we are already halfway through August, with no terms of reference, no sense of the trusts who are likely to be part of the review or no clarity on how the review will be conducted.
'Every woman and family should leave maternity and neonatal services whole, happy and healthy, and every member of maternity staff should start and end their shift knowing they have provided safe, good-quality care.
'At the moment, that simply isn't the case. Previous reviews and countless Care Quality Commission reports have flagged the same the systemic failings that are at the heart of the issues facing maternity and neonatal care issues time and time again: unsafe staffing, poor workplace cultures, and not listening to women.
'In spite of that, there has been no forward movement. Wes Streeting promised to change that. Thousands of midwives and maternity support workers, and the whole of the maternity community, are desperate for him to keep that promise and deliver the change we all want to see.'
The RCM has also urged the review to look at examples of good maternity care, as well as where services are not meeting standards of care.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
42 minutes ago
- The Sun
Alert over bacteria outbreak that's left 500 sick and 14 hospitalised from eating tomatoes
AT least 500 people have fallen ill after eating tomatoes found to contain salmonella. Some 14 required hospital admission, including eight adults and six children, following a meal in Barbastro, Spain. 4 4 Most patients, who were attending Somontano Wine Festival earlier this month, have been discharged, but three continue to receive treatment, Food Safety News reports. They are said to be suffering with symptoms compatible with gastroenteritis - an infection that causes inflammation of the stomach and intestines. This can trigger sudden diarrhoea, projectile vomiting, nausea, cramps, a fever, a loss of appetite, dehydration, aching limbs and headaches, according to the NHS. Symptoms usually appear up to a day after becoming infected and last less than a week. Officials say around 500 people are known to have experienced mild to moderate side effects from August 4. "But this is just an estimate," Nuria Gayán Margelí, general directorate of public health for the Government of Aragon, said. "There will be people who are affected and have not sought medical attention, and others who have been treated for similar, unrelated symptoms." Food samples were tested following the outbreak to identify the cause. Salmonella was found in toasted bread with crushed tomatoes "that were used as the base for several tapas". It was not detected in any other dishes, including sausages, tortillas, potatoes, minced meat, béchamel sauce, cheesecake or roasted vegetables. What is salmonella, what are the symptoms and treatment? But some kitchen tools, including blender blades and brushes used to spread the tomato on bread, tested positive for the bacteria - as did stool samples from those who fell ill. A deep clean of the outlet and all equipment was carried out, and no worker can return until given the all-clear. All remaining tomatoes were disposed of. 4 Salmonella is a bacteria that can cause food poisoning, sometimes called salmonellosis. It lives in the guts of animals and humans and spreads through contaminated poo. Food can become tainted if it's grown in dirty water, handled with dirty hands, or touches surfaces exposed to animal waste. This contamination can occur at any stage, from farm to fork, including irrigation with contaminated water, poor hygiene during harvesting, or cross-contamination during packaging. That's how fresh produce like tomatoes, especially when eaten raw, can end up crawling with the bug. 4 Salmonella is also commonly found in raw eggs, undercooked chicken and unwashed salad leaves. It can affect anyone, but young children, people over the age of 65 and those with weakened immune systems are at greater risk of becoming seriously ill, according to the Food Standards Agency. The most common symptoms are: Diarrhoea Stomach pain Fever Headache Nausea Vomiting General tiredness These can last up to seven days, but a small number of people take weeks to fully recover, the NHS says. Rare complications include blood poisoning, abscesses and joint pain. Reactive arthritis can also occur, which can last for years and be difficult to treat, the Centers for Disease Control and Prevention says. Patients with a salmonella infection should drink plenty of water and contact their GP if symptoms are severe or they persist. The NHS adds: "In most cases, it is generally advised to wait until 48 hours after having diarrhoea or sickness before returning to work, school or nursery." Salmonella is not usually fatal. The UK recorded 57 deaths due to the infection in 2017 and 2018, according to data compiled by the European Centre for Disease Prevention and Control (ECDC). In 2019, there were 8,398 cases, down from 8,838 the year before. But they shot to 10-year high in 2024, soaring by almost a fifth in a single year to more than 10,000.
The Independent
an hour ago
- The Independent
Patients warned not to turn to fake weight loss jabs after UK Mounjaro price hike
Medical experts have warned Britons not to turn to fake weight loss jabs after fears the Mounjaro price hike could make it unaffordable for people 'already struggling to pay for it'. The cost of the drug, dubbed the 'King Kong' of weight loss medicine, is set to triple in the UK after its US -owned company equalised costs in markets across the globe. A month's supply of the highest doses of the jab will rise from £122 to £330 - an increase of 170 per cent. Though this will not affect patients prescribed the jab on the NHS, it will affect thousands of people who are currently buying the medicine privately. Professor Claire Anderson, president of the Royal Pharmacist Society (RPS), said the price hike risks rendering the jabs out of reach for people already struggling to afford them. 'It's reassuring that NHS patients with obesity and type 2 diabetes will continue to access Mounjaro,' she told The Independent. 'However, rising private prescription costs may make Mounjaro unaffordable for people in deprived areas already struggling to pay for it.' She said the RPS urges anyone considering obtaining Mounjaro to do so only from a UK pharmacy that is registered with the General Pharmaceutical Council and with a valid prescription. She warned fakes could be harmful or non-effective and said: 'Counterfeit medicines from unregulated sources pose serious health risks—they can contain incorrect doses, harmful substances or no active ingredient at all.' She added that if patients If buying online, check the site displays the official green GPhC logo linking to the GPhC register. Professor Kamila Hawthorne, Chair of the Royal College of GPs, also urged patients to only use reputable outlets and to speak with their private provider if they are concerned about potential price increases to the drug. She said: 'If they are accessing medication through dubious online sources, or without a prescription, it can be a genuine threat to a patient's safety. In some cases, people may not be buying what they think they are, which is really dangerous.' Fake jabs for sale in the UK are already a huge concern, with thousands of fraudulent online pharmacies selling such products having been uncovered. Fake versions of Ozempic, another popular brand of weight loss jab, have been found being sold for as little as £13.70 per dose, along with counterfeit versions of other brands, including Rybelsus and Metformin pills, being offered from 24p. Researchers from Avast, a cybersecurity brand of the company Gen, who conducted the investigation, warned of the 'dangerous' threat of the global scam involving more than 5,000 fake pharmacy sites this year, which they say are being run by criminal networks. It comes amid the rapid rise of weight-loss medication in the UK – with around 1.5 million people, 4 per cent of households, currently using them. These weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. In June, the NHS offered Mounjaro to obese patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. Over the next three years, about 240,000 patients are expected to be eligible for the treatment. Mounjaro's owner Eli Lily said it would not raise the price paid by the NHS, and it was working with private healthcare providers to maintain access to the jab. The move reflects how the pharmaceutical industry is navigating policy changes in the US, by far its most lucrative market.
Daily Mail
2 hours ago
- Daily Mail
Mounjaro users panic over massive price hikes - experts reveal how to keep using weight loss jabs... for less
Mounjaro manufacturer Lilly sparked panic among slimmers yesterday after revealing it would more than double the price of the drug in the UK. The US pharmaceutical giant announced the cost would soar from September 1, with the wholesale price of a month's supply of the highest dose rising from £122 to £330. Lilly claimed it had initially launched Mounjaro in the UK at a price 'significantly below the European average to prevent delays in NHS availability' but that this must now change 'to ensure fair global contributions to the cost of innovation'. The announcement, however, does not affect the price the NHS pays, as the service has negotiated a heavily discounted rate for those getting the drug on prescription. But there are thought to be around 1.5 million people on weight loss drugs in the UK with more than half of them on Mounjaro—and estimates suggest nine in 10 pay for these drugs privately. Users flocked to social media warning denouncing the move, worried they were now left with no option but to come off the 'life changing' jab. 'I have no one to talk to about this and I'm freaking out,' one wrote on Reddit. 'Call it dramatic but I just cannot afford this, and this med is my only lifeline right now. I'm absolutely devastated. I don't know what to do.' Mounjaro price increases Mounjaro®▼ (tirzepatide) KwikPen® Dose Current UK List Price New UK List Price (From September) 2.5mg £92 £133 5mg £92 £180 7.5mg £107 £255 10mg £107 £255 12.5mg £122 £330 15mg £122 £330 Another said: 'I'm totally freaking out about it! I'm only about to go onto my 2nd pen now. The black market is going to be even more rife than ever due to this, fuming.' The main concern among slimmers is regaining weight after being forced to stop Mounjaro. Evidence suggests currently only around 2 to 10 per cent of people keep all their lost weight off if they stop taking the jabs, known collectively as GLP-1s. So is it possible to still access Mounjaro at a similar price? And crucially, what are options if you want to stay on the jabs but can't afford to? With the help of a team of experts, we explain everything you need to know about how to keep using weight loss jabs, for less... I already pay for Mounjaro privately - can I now get it on the NHS? Not necessarily. Only those who hit the body mass index (BMI) threshold set by the NHS may be prescribed weight-loss jabs. Patients must have a BMI of at least 40—severely obese—as well as four obesity-related conditions, including high blood pressure, high cholesterol, sleep apnoea, heart disease, osteoarthritis or diabetes. Next year, those with a BMI of over 35, along with four obesity-related conditions, will be offered the jabs. Then, in September 2026, those with a BMI of over 40 and just three related conditions will be able to access them on the NHS. Private clinics, however, can offer Mounjaro to patients with a BMI of over 30 or 27 if they also have at least one weight-related condition. 'There are lots of patients paying privately who want to switch to NHS treatment,' says Oxford GP Dr Helen Salisbury, 'but that won't happen overnight.' If I qualify for Mounjaro on the NHS, what are my next steps? Eligible patients need to make an appointment with their GP, which will likely be face-to-face in an effort to combat 'potential misuse'. The GP will assess medical records and, if necessary, contact other doctors who have recently treated the patient, to make sure they are a suitable candidate for treatment. If the prescription is approved, then patients will initially need to have monthly face-to-face appointments with a 'suitably trained healthcare professional', such as a nurse and monitored for potential side effects. GPs need to regularly review the patient's prescription, taking into account their BMI, comorbidities, side effects, and mental health, for at least the first year of treatment and possibly longer. I'm not eligible but can't afford to stay on Mounjaro from September—what are my options? Thousands of Mounjaro users could face a situation by the end of the month where they cannot afford to continue taking Mounjaro. But experts say it is possible to switch medication and begin a new weight loss jab. Thorrun Govind, a TV pharmacist and former chair of the Royal Pharmaceutical Society, told the Daily Mail: 'Patients can ask their provider to switch and a decision will then be taken together.' Toby Nicol, CEO at private weight loss jab provider CheqUp, meanwhile said: 'A huge number of people will be considering switching and it's important that they know that this is absolutely possible. 'Wegovy is now a much more affordable option and is also clinically proven as a highly effective drug. 'We don't want anyone to be priced out and think they have to take something which is unsafe. 'Do not buy from the cowboys. If the price is to good to be true, it probably is.' Experts, however, have warned against trying to 'microdose' remaining Mounjaro pens in an effort to prolong the drug and save money. The term, refers to counting clicks on pre–filled Mounjaro pens to deliver less than the prescribed dose—or even breaking them open. 'People are risking serious side effects from overdosing, as well as the potential for life–threatening infection,' said Professor Alex Miras, an endocrinologist at Ulster University. 'We cannot endorse it.' He added: 'Not only is contamination a risk, but it also reduces the effectiveness of the medication.' So which jab should I switch to? Pharmacists have said Wegovy is the most likely option. The drug, which contains the ingredient semaglutide, is made by Danish pharmaceutical giant Novo Nordisk. Kevin Joshua, the clinical lead at Juniper, an online pharmacy selling weight-loss jabs, said: 'For many, the pragmatic move is to switch to Wegovy—proven outcomes, a cardiovascular risk‑reduction indication in people living with overweight or obesity, and more predictable private costs.' Clinical trials have shown Mounjaro is the most effective of all the injections, with average weight loss of 20 per cent over 72 weeks. By comparison, Wegovy achieved average weight loss of around 14 per cent. Experts suggest this is because Wegovy mimics one hormone released by the body after a meal, to flip one appetite switch in the brain. Mounjaro, meanwhile, flips two. How can I make the switch safely? Given the two jabs contain different ingredients, how well the body tolerates them may differ. As with any medication, patients may need to adjust to the side effects of a new medicine. Dr Suhail Hussain, a GP for private online clinic Doctify, said: 'Mounjaro tends to be better tolerated in terms of gastrointestinal side effects than Wegovy, so patients may experience more nausea or vomiting.' Other common side effects of beginning a new GLP-1 medication includes nausea, diarrhoea, constipation and headaches. Ms Govind told Daily Mail that one way patients may make the switch is by 'taking your next semaglutide dose one week after your last Mounjaro injection, effectively replacing it without a break'. She added: 'This avoids a "hunger rebound" that can happen if you leave a long gap. 'There is no direct dose conversion between tirzepatide and semaglutide. So you might switch to a low dose semaglutide and then go up in dose.' Should I come off Mounjaro completely first before starting a new medication? Experts have repeatedly warned against completely stopping taking weight loss jabs suddenly over fears of side effects such as body aches, as well as regaining the weight lost on the drug. But according to pharmacists, patients must first completely come off Mounjaro before switching to a new jab, such as Wegovy. This is because the GLP-1 jabs affect the same hormones and could 'massively increase the risk of side effects', Ms Govind told the Daily Mail. There is also not clear long term evidence yet on the long term issues this could cause, she added. 'For patients who are currently on Mounjaro, it may require a period of abstinence of several weeks before switching on an alternative,' Dr Leyla Hannbeck also told the Daily Mail. 'Your pharmacist will be able to advise you on the switch.' Ms Govind added: 'Typically it's seven days between the last tirzepatide and the first semaglutide dose. 'But it depends on the side effects that the patient has experienced and their tolerability to those side effects.'
